Company Analysis

iBio, Inc. (IBIO)

Nasdaq: IBIO · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2008
Grade3.4
◀ Past 2.1● Present 3.4▶ Future 4.0
1 est.

Who runs iBio, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Brenner Martin
Chief Executive Officer and Chief Scientific Officer. First filing Jan 2021, latest Mar 23, 2026, 13 filings in all.
Officers reporting now
4
of 11 people with a filing in the last fifteen months
Directors reporting now
7
27 people on the record since 2008
Officerssales are open-market, Oct 15, 2025 to Oct 15, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Carr MollyChief Medical OfficerAug 2026Aug 4, 2026none
Banjak MarcChief Legal OfficerAug 2024Mar 27, 2026none
Brenner MartinChief Executive Officer and Chief Scientific OfficerJan 2021Mar 23, 2026none
Duran FelipeChief Financial OfficerFeb 2023Mar 23, 2026none
Directorssales are open-market, Oct 15, 2025 to Oct 15, 2026
NameRoleFirst filingLatest filingSales, 12 months
Arkowitz DaviddirectorNov 2024Oct 15, 2026none
Clark William DdirectorAug 2021Oct 15, 2026none
Kropotova AlexandradirectorOct 2020Oct 15, 2026none
Parada Antonio Bernardino GuimaraesdirectorDec 2024Oct 15, 2026none
Sender GarydirectorOct 2020Oct 15, 2026none
Stoner ElizabethdirectorMay 2026Oct 15, 2026none
Schimmelpennink Evert B.directorJun 2021Nov 24, 2025none
Earlier names on the record19, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton IBIO · research, not advice